

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
22 February 2024 (22.02.2024)



(10) International Publication Number
WO 2024/039599 A1

(51) International Patent Classification:

C07D 317/54 (2006.01) A61K 31/421 (2006.01)
C07D 317/58 (2006.01) A61P 25/00 (2006.01)
A61K 31/36 (2006.01)

NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:

PCT/US2023/030140

(22) International Filing Date:

14 August 2023 (14.08.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/398,703 17 August 2022 (17.08.2022) US
63/471,369 06 June 2023 (06.06.2023) US

(71) Applicant: **TRANSCEND THERAPEUTICS, INC.**
[US/US]; 520 Broadway, New York, New York 10012 (US).

(72) Inventors: **COTE, Bernard**; 43 Alfred-DesRochers Street,
Notre-Dame-de-L'Île-Perrot, Québec J7W 0T5 (CA). **SCH-
MIDT, Jennifer Louise**; 45 Harvard Street, Garden City,
New York 11530 (US). **STOGNIEW, Martin**; 7811 Math-
ern Ct., Lakewood Ranch, Florida 34202 (US).

(74) Agent: **PASSNER, Jonathan M.** et al.; PEARL COHEN
ZEDEK LATZER BARATZ LLP, 7 Times Square, 19th
Floor, New York, New York 10036 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,


(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments (Rule 48.2(h))

(54) Title: PHENETHYLAMINES AND CATHINONES PRECURSORS

FIGURE 1 B



(57) Abstract: The subject matter disclosed generally relates to phenethy-
lamines or cathinones covalently bound to a chemical moiety in a prodrug
form. The presently described technology allows slow/sustained/controlled
delivery of the parent phenethylamines or cathinones into the blood system
in a manner that increase the duration of therapeutic efficacy, ease of ap-
plication, patient compliance and/or a combination of these characteristics
when administered, in particular, orally. Additionally, the described tech-
nology allows gradual release of the parent phenethylamines or cathinones
over an extended period of time thereby eliminating spiking of drug levels
which lessen cardiovascular stress, addiction/abuse potential and/or other
common stimulant side effects associated with psychoactive compounds.

WO 2024/039599 A1